实体器官移植中，巨细胞病毒血清学“供者阳性、受者阴性”（D+/R-）的组合为什么感染风险最高？临床如何预防？
In solid organ transplantation, why does the CMV serological combination of donor-positive and recipient-negative (D+/R-) carry the highest infection risk, and how is it prevented in clinical practice?
供者器官内潜伏的巨细胞病毒可在缺乏特异性免疫的受体中被激活，构成最严重的原发感染，可表现为肺炎、肠炎并增加排斥风险。预防为口服缬更昔洛韦3–6个月（不同器官疗程有别），并定期监测血浆病毒DNA载量；同时避免免疫抑制过度及使用未经白细胞滤除的血制品。
Latent cytomegalovirus within the donor organ reactivates in a recipient who lacks CMV-specific immunity, producing primary infection, the most severe pattern, with possible pneumonitis, enteritis and heightened rejection risk. Prevention consists of oral valganciclovir for three to six months depending on the organ, scheduled plasma viral-DNA surveillance, use of leukocyte-reduced blood products, and avoidance of overly intense immunosuppression, which together markedly lower early CMV disease incidence.
难度 进阶 · 适合 初中(12-15)
CC BY 4.0 · 来源待核验 · Source pending review
来源 · Source
出处备注：著录含书名，但缺版次 / 出版社 / 年份中的一部分，需编辑补全后才能做独立比对。
美国移植学会感染性疾病社区实践委员会巨细胞病毒诊治指南，《Clinical Transplantation》2019年
AST Infectious Diseases Community of Practice CMV Guidelines, Clinical Transplantation, 2019
#巨细胞病毒 #移植感染 #缬更昔洛韦
为什么接受他人器官移植后，患者通常需要长期甚至终身服用免疫抑制剂？
After receiving someone else's organ, why do patients usually need long-term, often lifelong, immunosuppressive drugs?
供者器官表面的HLA抗原被受者免疫系统识别为“非己”，T细胞经直接与间接两条同种识别途径被激活，进而攻击移植物的血管和实质。人类尚不能可靠地诱导持久免疫耐受，自行减药、停药极易诱发急性排斥或慢性移植物失功。因此多数患者需终身维持免疫抑制方案，并在抗排斥保护与感染、肿瘤风险之间不断权衡调整。
Donor organs carry HLA antigens that the recipient's immune system reads as foreign; T cells become activated through direct and indirect pathways of allorecognition and then attack the graft's vessels and tissue. Reliable, lasting immune tolerance cannot yet be routinely achieved in humans, and self-directed dose cuts or stopped medication readily trigger acute rejection or chronic graft loss. Most recipients therefore continue maintenance immunosuppression for life, continually weighing anti-rejection protection against infection and cancer risks.
难度 进阶 · 适合 大众
CC BY 4.0 · 来源待核验 · Source pending review
来源 · Source
出处备注：著录含书名，但缺版次 / 出版社 / 年份中的一部分，需编辑补全后才能做独立比对。
Halloran PF．肾移植的免疫抑制药物．《新英格兰医学杂志》，2004；351(26)：2715-2729
Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med. 2004;351(26):2715-2729
#器官移植 #免疫抑制 #排斥反应 #HLA
实体器官移植术后服用他克莫司的患者，为什么必须定期检测血药谷浓度，而不能长期按固定剂量服药？
Why must solid organ transplant recipients taking tacrolimus have regular blood trough-level checks rather than staying on a fixed dose?
他克莫司治疗窗很窄，个体间肠道吸收和经CYP3A代谢差异极大，同一剂量在不同患者体内的血药浓度可相差数倍。浓度过低不足以抑制T细胞活化，容易发生急性排斥；过高则引起肾毒性和震颤等神经毒性，还会升高血糖。定期测定谷浓度并结合肝肾功能调整剂量，可在抗排斥效力与毒性之间取得平衡；通常移植早期目标浓度较高，之后逐步下调。
Tacrolimus has a narrow therapeutic index, and intestinal absorption and CYP3A-mediated metabolism vary enormously between individuals, so the same dose yields blood levels differing severalfold. Levels too low fail to suppress T-cell activation, inviting acute rejection; levels too high cause nephrotoxicity, tremor and other neurotoxicity, and raise glucose. Regular trough measurements with doses adjusted to liver and kidney function balance rejection control against toxicity; targets start higher right after transplantation and step down over time.
难度 进阶 · 适合 大众
CC BY 4.0 · 已核验 · Verified 2026-11-04
来源 · Source
Staatz, Tett,《Clinical Pharmacokinetics and Pharmacodynamics of Tacrolimus in Solid Organ Transplantation》,Clinical Pharmacokinetics,2004 (DOI: 10.2165/00003088-200443100-00001)
Staatz, Tett, 'Clinical Pharmacokinetics and Pharmacodynamics of Tacrolimus in Solid Organ Transplantation', Clinical Pharmacokinetics, 2004, DOI: 10.2165/00003088-200443100-00001
独立核验依据 · Independent verification: 核验依据 1 Crossref DOI 10.2165/00003088-200443100-00001
#他克莫司 #治疗药物监测 #免疫抑制